Cancer vaccines

British Journal of Cancer

Volumn 82, Issue 10, 2000, Pages 1619-1624

  Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIGEN; BCG VACCINE; CANCER VACCINE; GANGLIOSIDE; TUMOR ANTIGEN;

BACTERIAL INFECTION; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BACTERIAL INFECTIONS; BCG VACCINE; CANCER VACCINES; CLINICAL TRIALS; GENE THERAPY; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034091997     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Alexandroff AB, Jackson AM, O'Donnell MA and James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353(9165): 1689-1694
2. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL and Kwak LW (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5(10): 1171-1177
3. Bjorck P (1999) Development of dendritic cells and their use in tumour therapy. Clin Immunol 92(2): 119-127
4. Boon T, Coulie PG and Van den Eynde B (1997) Tumour antigens recognised by T cells. Immunol Today 18(6): 267-268
5. Browning M and Dalgleish AG (1996) Introduction and historical perspective. In: Tumour Immunology - Immunotherapy and Cancer Vaccines (Cancer, Clinical Science in Practice). Dalgleish AG, Browning M (eds) Cambridge University Press: London and New York
6. Cameron RB, Spiess PJ and Rosenbery SA (1990) Synergistic antitumour activity of tumour-infiltrating lymphocytes, interleukin 2, and local tumour irradation. Studies on the mechanism of action. J Exp Med 17(1): 249-263
7. Cascinelli N, Rumke P, Mackie R, Morabito A and Bufalino R (1989) The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother 28(4): 282-286
8. Coley WB (1991) The treatment of malignant tumours by repeated inoculations of erysipelas. With a report of ten original cases, 1893. Clinical Orthopaedics 262: 3-11
9. Dalgleish AG (1996) The case for therapeutic vaccines. Melanoma Research 6: 5-10
10. Dalgleish AG (1999) The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines. QJM 347-359
11. Di Nicola M, Siena S, Bregni M, Longoni P, Magni M, Milanesi M, Matteucci P, Mortarini R, Anichini A, Parmiani G, Drexler I, Erfle V, Sutter G and Giannni AM (1998) Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. Cancer Gene Ther 5(6): 350-356
12. French RR, Chan HT, Tutt AL and Glennie MJ (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5(5): 548-553
13. Fuchs EJ and Matzinger P (1996) Is cancer dangerous to the immune system? Semin Immunol 8(5): 271-280
14. Gilboa E (1999) How tumours escape immune destruction and what we can do about it. Cancer Immunol Immunother 48(7): 382-385
15. Goto S, Sato M, Kaneko R, Ioth M, Sato S and Takeuchi S (1999) Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 48(8): 435-442
16. Guinan P, Toronchi E, Shaw M, Crispin R and Sharifi R (1982) Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 20(4): 401-403
17. Heriot AG, Marriott JB, Cookson S, Kumar D and Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer: (in press)
18. Hrouda D, Todryk SM, Perry MJA, Souberbielle BE, Kayaga J, Kirby RS and Dalgleish AG (2000) Allogeneic whole rumour cell vaccination in the rat model of prostate cancer. Br J Urol: (submitted)
19. Hrouda D, Baban B, Dunsmuir WD, Kirby RS and Dalgleish AG (1998) Immunotherapy of advanced prostate cancer: a Phase I/II trial using Mycobacterium vaccae (SRL-172). Br J Urol 82: 568-573
20. Hsueh EC, Famatiga E, Gupta RK, Qi K and Morton DL (1998a) Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (Cancer Vax): correlation with survival. Ann Surg Oncol 5(7): 595-602
21. Hsueh EC, Gupta RK, Qi K and Morton DL (1998b) Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16(9): 2913-2920
22. Hurle R, Losa A, Manzetti A and Lembo A (1999) Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54(2): 258-263
23. Kayaga J, Souberbielle BE, Shiekh N, Morrow WJW, Scott-Taylor TH, Vile R and Dalgleish AG (1999) Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Therapy 6: 1475-1481
24. Knight BC, Souberbielle BE, Rizzardi GP, Ball SE and Dalgleish AG (1996) Allogeneic murine melanoma cell vaccine - a model for the development of human allogeneic cancer vaccine. Melanoma Research 6(4): 299-306
25. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F and Ritter G (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12(5): 1036-1044
26. Ludewig B, Odermatt, Ochsenbein AF, Zinkernagel RM and Hengartner H (1999) Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev 169: 45-54
27. MacLean GD, Reddish MA, Koganty RR and Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 19(1): 59-68
28. Maraveyas A, Baban B, Kennard D, Rook GAW, Westby M, Grange JM, Lydyard P, Stanford JJ, Jones E, Selby P and Dalgleish AG (1999a) Possible improved survival of patients with Stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin 2 in peripheral blood lymphocytes. Ann Oncol 10.7: 817-824
29. Maraveyas A, Compton L, Dunleavey R, Sage D, Naverette C, Mortion D and Dalgleish A (1999b) 3-Fold increase in survival for stage IV melanoma patients treated with MCV allogeneic vaccine: Confirmation of previous phase II data. Eur J Cancer 35(4): 356
30. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek La, Chang C, Davtyan DG, Gupta RK and Elashoff (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216(4): 463-482
31. Nathanson L (1979) Immunotherapy of melanoma. J Cutan Pathol 6(3): 213-226
32. Nathanson L, Schoenfeld D, Regelson W, Colsky J and Mittelman A (1979) Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer 43(5): 1630-1635
33. Nauts HC and McLaren JR. Coley Toxins - the first century. Adr Exp Med Biol 267: 483-500
34. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP and Harris AL (2000) Angiogenesis and suppression of cell mediated immunity precede and play a central role in the pathogenesis of malignant disease. Eur J Cancer (in press).
35. Pawelec G (1999) Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother 48(7): 343-345
36. Perry MJA, Hrouda D and Dalgleish AG (2000) Prospects for vaccination in prostate cancer. Drugs Aging: (in press)
37. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marcincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE (1998) Immunological and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4(3): 321-327
38. Scott-Taylor TH, Pettingale R, Clarke I, Stuhler G, Lararth MC, Walden PM and Dalgleish AG (2000) Human tumour and dendritic cell for hybrids generated by electrofusion: potential for cancer vaccines. Biochem Biophys Acta: (in press)
39. Siena S, Di Nicola M, Bregni M, Mortarini R, Anichini A, Lombardi L, Ravagnani F, Parmiani G and Gianni AM (1995) Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 23(14): 1463-1471
40. Souberbielle BE, Knight BC, Morrow WJW, Darling D, Fraziano M, Marriott JB, Cookson S, Farzaneh F and Dalgleish AG (1996) Comparison of IL-2 and IL-4 transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine. Gene Therapy 3(10): 853-858
41. Souberbielle BE, Westby M, Ganz S, Kayaga J, Mendes R, Morrow WJW and Dalgleish AG (1998) Comparison of four strategies in the B16-F10 melanoma model. Gene Therapy 5(11): 1447-1455
42. Srivastava PK and Udonon H (1994) Heat shock protein peptide complexes in cancer immunotherapy. Curr Opin Immunol 6(5): 728-732
43. Tan JK and Ho VC (1993) Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. Journal of Dermatological Surgery and Oncology 19(11): 985-990
44. Thun MJ (1997) Aspirin and gastrointestinal cancer. Adv Exp Med Biol 400A: 395-402
45. Tureci O, Sahin U and Pfreundschuh M (1997) Serological analysis of human tumour antigens: molecular definition and implications. Mollecular Medicine Today 3(8): 342-349
46. Vermorken JB, Claessen Am, Van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr and Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150): 345-350
47. Vile R, Souberbielle B and Dalgleish AG (1996) Tumour Vaccines. In: Immunotherapy in Cancer, Gore M and Riches P (Eds), John Wiley & Sons Ltd: Chichester
48. Vuvan H, Fiere D, Doillon M, Martin C, Coiffier B, Felman P, Bryon PA, Favre-Gilly J and Revol L (1978) BCG therapy in acute non lymphoid leukaemias. Scandinavian Journal of Haematology 21(1): 40-46
49. Walker PR, Saas P and Dietrich PY (1997) Role of Fas ligand (CD95L) in immune escape: the tumour cell strikes back. J Immunol 158(10): 4521-4524
50. Wang RF and Rosenberg SA (1999) Human tumour antigens for cancer vaccine development. Immunol Rev 170: 85-100
51. Zuhrie SR, Harris R, Freeman CB, MacIver JE, Geary CG, Delamore IW and Tooth JA (1980) Immunotherapy alone vs no maintenance treatment in acute myclogenous leukaemia, Br J Cancer 41(3): 372-377